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Numerous common genetic variants have been linked to blood pressure, but no underlying mechanism has 
been elucidated. Population studies have revealed that the variant rs5068 (A/G) in the 3′ untranslated region 
of NPPA, the gene encoding atrial natriuretic peptide (ANP), is associated with blood pressure. We selected 
individuals on the basis of rs5068 genotype (AG vs. AA) and fed them a low- or high-salt diet for 1 week, after 
which they were challenged with an intravenous saline infusion. On both diets, before and after saline admin-
istration, ANP levels were up to 50% higher in AG individuals than in AA individuals, a difference comparable 
to the changes induced by high-salt diet or saline infusion. In contrast, B-type natriuretic peptide levels did not 
differ by rs5068 genotype. We identified a microRNA, miR-425, that is expressed in human atria and ventricles 
and is predicted to bind the sequence spanning rs5068 for the A, but not the G, allele. miR-425 silenced NPPA 
mRNA in an allele-specific manner, with the G allele conferring resistance to miR-425. This study identifies 
miR-425 as a regulator of ANP production, raising the possibility that miR-425 antagonists could be used to 
treat disorders of salt overload, including hypertension and heart failure.
Introduction
The average adult from the US consumes nearly 10 grams of salt 
per day, far in excess of the recommended amounts (1, 2). High-
salt intake is linked to hypertension and cardiovascular disease (3, 
4). The natriuretic peptide system plays a central role in the physi-
ologic response to salt intake. Synthesized by the heart in response 
to increased intravascular volume; atrial and B-type natriuretic 
peptides (ANP and BNP, respectively) bind their receptors, partic-
ulate guanylyl cyclases, which catalyze and promote the produc-
tion of cyclic guanosine monophosphate (cGMP); and promote 
natriuresis, diuresis, and vasodilation.
Evidence from population genetic studies suggests that variation 
in the plasma levels of natriuretic peptides may alter susceptibility 
to cardiovascular disease via effects on blood pressure. Common 
SNPs in the chromosomal region containing NPPA and NPPB, 
the genes encoding the ANP and BNP propeptides, are associated 
with circulating levels of the natriuretic peptides (5). Large-scale 
epidemiologic studies have established that the same variants are 
associated with blood pressure (5, 6). The SNP that is associated 
with plasma ANP levels most strongly is rs5068 (A/G): carriers of 
the rs5068 minor G allele have a 15% lower risk of hypertension 
than do those with 2 copies of the major A allele.
As with all complex traits, the majority of blood pressure–related 
SNPs are noncoding, and they are typically located within large 
blocks of correlated SNPs by virtue of linkage disequilibrium. 
Thus, identifying causal SNPs and the mechanisms by which they 
act presents significant challenges. Indeed, although genome-wide 
association studies have yielded a long list of candidate SNPs asso-
ciated with blood pressure, the only variants for which a mech-
anism has been established are rare mutations in families with 
Mendelian forms of hypertension or hypotension (7).
The rs5068 SNP is located in the 3′ untranslated region (UTR) 
of the NPPA gene. It has recently been recognized that small 
noncoding RNAs called microRNAs (miRNAs) can play a role 
in posttranscriptional regulation of gene expression by bind-
ing to 3′UTRs (8, 9). Binding of miRNAs to mRNAs typically 
requires complementarity of a seed sequence at positions 2–7 
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of the 5′ end of the miRNA (10). We hypothesized that rs5068 
is a causal variant and that the mechanism of its effect on ANP 
levels involves interference with miRNA binding.
Results and Discussion
Epidemiologic studies have shown differences in plasma natri-
uretic peptide concentrations among rs5068 genotypes (5), but 
these differences were identified in the context of random salt 
intake and other sources of variation inherent to community- 
based studies. To minimize this variation and provide mecha-
nistic insights into the association of rs5068 with ANP levels 
and blood pressure, we undertook a high-resolution physio-
logic study of healthy subjects who were selected on the basis 
of their rs5068 genotype and maintained on defined low- and 
high-salt diets.
We genotyped the rs5068 variant in 699 healthy, normoten-
sive individuals of European ancestry between the ages of 18 
and 40. Overall, 645 (92%) individuals had 2 copies of the 
major A allele (AA), and 54 (8%) had at least one copy of the 
minor G allele (AG or GG). Detailed characteristics of the 23 
AA individuals and 8 AG individuals who participated in the 
physiologic study are shown in Supplemental Table 1 (supple-
mental material available online with this article; doi:10.1172/
JCI67383DS1).
Subjects were placed on a study diet for 2 weeks, consisting of 
1 week on a high-sodium diet (200 mEq/d) and 1 week on a low-
sodium diet (10 mEq/d), in random order. Mean 24-hour urine 
sodium was 22 mmol after a week on the low-sodium diet and 
142 mmol after a week on the high-sodium diet. AG individuals 
had higher plasma levels of N-terminal proANP (Nt-proANP) 
than AA individuals after 1 week on either a low- or a high-
sodium diet (49% and 32%, respectively; P = 0.016 for overall 
genotype effect). The transition from a low- to high-sodium 
diet was associated with a 55% increase in Nt-proANP levels 
(P < 0.001), a difference that was similar in both genotype 
groups (diet-by-genotype interaction, P > 0.8). AG individuals 
on a low-sodium diet had plasma Nt-proANP concentrations 
that were comparable to those of AA individuals on a high-
sodium diet. These findings suggest that rs5068 influences the 
“set point” of circulating ANP on both low- and high-sodium 
backgrounds. The magnitude of the genetic effect is similar to 
that of a marked (20-fold) change in salt intake.
To ascertain whether rs5068 influences the ability of ANP levels 
to increase in response to intravascular volume expansion, plasma 
Nt-proANP levels were measured during and after a saline chal-
lenge. In the group as a whole, saline administration increased 
plasma Nt-proANP levels by 64% on a low-sodium diet background 
(Figure 1A) and 59% on a high-sodium diet background (Figure 
1B). Mean plasma Nt-proANP concentrations at all time points 
during and after the saline infusion were higher in AG individuals 
than in AA individuals (P = 0.018 for genotype effect). There was 
no evidence of a saline-by-genotype interaction (P = 0.84).
After 1 week on a low-sodium diet, saline administration 
increased plasma cGMP levels in both AG and AA individuals 
(Supplemental Figure 1A). After 1 week on a high-sodium diet, 
saline administration increased plasma cGMP levels by 37% in AG 
individuals and 16% in AA individuals (P = 0.03 for genotype effect 
and P < 0.001 for saline infusion; Supplemental Figure 1B). The 
associations of genotype and cGMP levels were consistent with 
those observed for circulating ANP levels.
Among the normotensive, young adults in our genotype-
directed study, no significant increases were noted in systolic or 
diastolic blood pressure with the transition from a low-sodium 
diet to a high-sodium diet, before or after saline infusion. How-
ever, there were trends toward lower systolic blood pressures in 
AG individuals compared with those in AA individuals after the 
high-salt diet (112 vs. 117 mmHg; P = 0.10) and after the saline 
infusion on a low-sodium background (109 vs. 114 mmHg; 
P = 0.06; Supplemental Table 2). We did not observe an effect 
of rs5068 genotype on urine volume or sodium excretion in 
response to saline infusion (P > 0.3).
Plasma N-terminal proBNP (Nt-proBNP) and mature BNP levels 
were higher on a high- than on a low-sodium diet and after saline 
infusion, but levels did not differ by rs5068 genotype (Supplemen-
tal Figure 2, A and B, and Supplemental Figure 3, A and B; P > 0.5). 
These findings support the specificity of the effect of the rs5068 
variant on ANP levels.
Although cardiac tissues are primarily responsible for ANP 
biosynthesis, the NPPA gene is expressed at low levels in a wide 
variety of cell types. We examined whether NPPA mRNA levels 
in the blood of 2,246 Framingham Heart Study participants 
varied by rs5068 genotype. NPPA expression was higher in indi-
viduals with at least 1 copy of the G allele (n = 203) than in AA 
Figure 1
The effect of genotype and dietary sodium on plasma Nt-proANP levels 
during saline challenge is shown after 1 week of a (A) low-salt diet or 
(B) high-salt diet (P = 0.018 for genotype effect, P < 0.001 for diet and 
saline effects). Samples for measurement of plasma Nt-proANP levels 
were obtained at baseline and hourly for 8 hours after the start of saline 
infusion. AA, rs5068 major homozygote; AG, rs5068 heterozygote.
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(n = 2,043) individuals (P = 2 × 10–18). We also measured NPPA 
mRNA levels in lymphoblasts (Coriell Institute) with AG (n = 4) 
and AA (n = 5) genotypes. NPPA mRNA levels were 2-fold higher 
in the cells with the AG genotype (P = 0.04). These findings sug-
gest that rs5068 acts by altering NPPA gene transcription or 
mRNA stability, rather than by altering secretory mechanisms 
or the clearance of the peptide from the circulation.
To identify an inhibitory miRNA that targets the NPPA rs5068 
allele associated with lower plasma ANP levels, miRNA databases 
(miRanda, ref. 11; TargetScan, ref. 10; and MicroSNiPer, ref. 12) 
were screened to generate a list of miRNAs predicted to interact 
with the NPPA 3′UTR containing the rs5068 A allele. We identified 
3 miRNAs that were predicted to bind at least 7 bases of the NPPA 
mRNA spanning the rs5068 A allele: miR-425, miR-4770, and 
miR-196a-3p (Supplemental Figure 4). miR-425 and miR-4770, 
but not miR-196a-3p, were detected in cardiac tissues from heart 
transplant donors without cardiovascular disease (n = 5). miR-425 
levels were similar in left atrium and left ventricle. In a separate 
study, we found that miR-425 levels in left atrial (n = 3) and ven-
tricular tissues (n = 4) obtained from patients undergoing aortic 
valve replacement for aortic stenosis were similar to those in left 
ventricular tissues from heart transplant donors (n = 3).
miRNA function was assessed in COS-7 cells transfected with 
luciferase reporter constructs containing the 3′UTR from NPPA 
major or minor alleles (major-LUC and minor-LUC, respectively). 
Transfection of miR-425 reduced relative luciferase activity in 
cells containing the major-LUC construct (P = 0.005; Figure 2A) 
but not in cells containing the minor-LUC construct. Transfec-
tion of miR-4770 and miR-196a-3p failed to alter relative lucifer-
ase activity (P = NS; data not shown).
Having determined that miR-425 transfection decreased lucifer-
ase activity in the presence of the A but not the G allele, we tested 
whether endogenous miR-425 levels regulate NPPA expression. 
Transfection of an anti–miR-425 increased relative luciferase activ-
ity in cells containing the major-LUC construct (P = 0.02; Figure 
2B) but not in cells containing the minor-LUC construct.
To confirm that the single base pair change at rs5068 was suf-
ficient to alter the binding of miR-425 to the NPPA 3′UTR, we 
constructed a modified miR-425 in which a single base in the 
Figure 2
Allele-specific effects of miR-425, anti–miR-425, and a modified miR-425 on luciferase activity encoded by firefly luciferase-NPPA 3′UTR 
constructs. The ratio of firefly luciferase activity to renilla luciferase activity was normalized to that in cells transfected with a plasmid directing 
expression of luciferase without the NPPA 3′UTR (relative luciferase activity). Data are expressed as mean ± SEM (n = 6). Each experiment 
was repeated 3 times with similar results. (A) miR-425 reduces activity of the NPPA major-LUC construct but not the NPPA minor-LUC con-
struct. (B) Anti–miR-425 increases activity of the NPPA major-LUC construct but not the NPPA minor-LUC construct. (C) A modified miR-425 
targeting the NPPA 3′UTR minor allele reduces activity of the NPPA minor-LUC construct but not the NPPA major-LUC construct.
Figure 3
miR-425 transfection reduces NPPA mRNA levels and secretion of 
Nt-proANP immunoreactivity in human cardiomyocytes derived from 
induced pluripotent stem cells. Cardiomyocytes (~4 × 105 per well) were 
transfected with miR-425 or a control miRNA. Twenty-four hours later, 
cells were washed and incubated in 1 ml of media. After an additional 
48 hours, cells and media were harvested. (A) NPPA mRNA levels 
relative to those in cells transfected with control miRNA. (B) Concentra-
tions of Nt-proANP immunoreactivity in the cell supernatant. Data are 
expressed as mean ± SEM (n = 4).
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seed sequence was changed to complement the minor G allele of 
rs5068. In contrast to miR-425, the modified miR-425 suppressed 
expression of the minor-LUC construct (P = 4 × 10–5; Figure 2C) 
but not the major-LUC construct.
We examined whether the NPPA allele-specific effects of miR-
425 lead to altered production of the ANP peptide. In COS-7 cells 
transfected with an NPPA cDNA expression plasmid containing 
the rs5068 major A allele, cotransfection of miR-425 reduced 
release of Nt-proANP into the media (P = 0.008, Supplemen-
tal Figure 5). In contrast, transfection of miR-425 did not alter 
Nt-proANP release from cells cotransfected with the NPPA expres-
sion plasmid containing the rs5068 minor G allele (P = 0.40; 
P = 1 × 10–5 for genotype effect).
To determine whether miR-425 could regulate endogenous 
NPPA gene expression, we transfected the miRNA into human car-
diomyocytes derived from induced pluripotent stem cells. Com-
pared with transfection of a negative control miRNA, transfection 
of miR-425 into cardiomyocytes reduced NPPA mRNA levels by 
66% (P = 0.0005; Figure 3A) and secretion of Nt-proANP by 56% 
(P = 0.00001; Figure 3B).
Taken together, these findings provide strong evidence that 
rs5068 is the causal variant underlying the previously reported 
blood pressure association, clarify the molecular mechanism by 
which rs5068 acts on ANP levels, and identify miR-425 as a novel 
regulator of the natriuretic peptide system.
Our findings illustrate the potential importance of interactions 
among miRNAs, polymorphisms in noncoding regions of the 
genome, and responses to environmental factors such as salt intake. 
It has been postulated that interference with miRNA binding is an 
important mechanism by which noncoding genetic variants iden-
tified by genome-wide association studies may exert their actions. 
However, to our knowledge, this study provides the first example of 
this phenomenon for a validated blood pressure association. Inter-
estingly, rs5068 had a substantial effect on the ANP “set point,” 
without altering the responsiveness of ANP to salt loading. This 
observation could have implications for future therapies based on 
miR-425, as it might be desirable to shift basal plasma ANP levels 
without changing the ability of the system to respond to stimuli.
Several limitations of the study merit consideration. We stud-
ied young, healthy, normotensive volunteers in order to minimize 
interference from comorbidities or medication use. In individuals 
with hypertension or older age, the transition from low- to high-
sodium diet has been associated with an increase in blood pressure 
(3). Our study was not designed to examine whether the rs5068 
variant is associated with salt-induced changes in blood pressure, 
because 1 week of a high-salt diet does not raise blood pressure in 
healthy, normotensive individuals (13) and because the associa-
tion of rs5068 with blood pressure and hypertension has already 
been established (5, 6). In addition, we studied only individuals of 
European ancestry, because, to date, it has not been established 
that rs5068 is associated with plasma ANP levels in populations 
of non-European ancestry, in whom the minor allele frequency is 
exceedingly low or zero.
In summary, we have identified a novel mechanism underlying 
blood pressure regulation and salt homeostasis by way of a com-
mon single base pair change in the NPPA gene that prevents bind-
ing of miR-425 and results in higher ANP levels. Our findings 
illustrate that common genetic variants can have a relatively large 
influence on physiologic responses, even if their association with 
clinical traits is more modest, presumably due to the multifacto-
rial determination of these traits and compensatory mechanisms. 
Indeed, the genetic effect of rs5068 on circulating Nt-proANP lev-
els is comparable to the environmental change induced by switch-
ing from an extremely low-salt diet (230 mg/d) to a diet with salt 
content typical of a Western diet (4,600 mg/d). Future studies are 
warranted to determine whether knowledge of rs5068 genotype 
could facilitate tailored strategies for the prevention and treat-
ment of hypertension. Our findings also raise the possibility that 
antagonists of miR-425–mediated suppression of NPPA expres-
sion could be used to treat disorders of salt overload, including 
hypertension and its complications.
Methods
A detailed description of the methods is provided in the Supplemental 
Methods.
Statistics. Repeated-measures ANOVA was used to assess the effect of 
genotype, diet, and intravenous saline on plasma Nt-proANP, Nt-proBNP, 
BNP, and cGMP levels. Gene expression data from the Framingham Heart 
Study have been deposited in dbGAP (National Center for Biotechnology 
Information, Bethesda, Maryland, USA; accession no. phs000007.v19.
p7). For relative luciferase activity, mRNA levels, and culture medium 
Nt-proANP concentrations, we performed 2-sample or paired t tests, as 
appropriate. All analyses were conducted using SAS. A 2-sided P value of 
less than 0.05 was considered statistically significant. Data are presented 
as mean ± SEM in the figures.
Study approval. The protocol was approved by the Partners Human 
Research Committee. All subjects provided informed consent.
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